News briefing: Pfizer kickstarts PhIII trial for DMD gene therapy, outracing Sarepta; Teva's reformulated schizophrenia shot touts win in late-stage study
In the race to bring the first gene therapy for Duchenne muscular dystrophy into a Phase III trial, Pfizer has come out on top over competitor Sarepta, dosing its first patient in the CIFFREO study, the pharma giant said Thursday.
CIFFREO is expected to enroll 99 male patients, ages 4 through 7, across 55 clinical trial sites in 15 countries, Pfizer said. The first of those patients were administered Pfizer’s therapy, dubbed PF-06939926, on Dec. 29 at a Barcelona site.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.